WUXI BIO (02269): Miao Jingwen appointed as non-executive director.
Wu Yibing, Ph.D., has resigned as of November 20, 2024, in an announcement from WuXi Biologics (02269).
WUXI BIO (02269) announces that, effective from November 20, 2024, Dr. Wu Yibing has resigned as a non-executive director and member of the Board's decision-making committee to dedicate more time to other personal matters. Ms. Miao Jingwen has been appointed as a non-executive director and member of the decision-making committee.
Related Articles
CITIC TELECOM (01883) announces annual financial results, with a net profit attributable to shareholders of HK$920 million, an increase of 1.1% year on year.
BAO PHARMA-B(02659): KJ101 received clinical trial approval for new indications.
SWIRE PROPERTIES (01972) released its annual performance with a net profit attributable to shareholders of HK$8.62 billion, representing a 27% year-on-year increase.
CITIC TELECOM (01883) announces annual financial results, with a net profit attributable to shareholders of HK$920 million, an increase of 1.1% year on year.
BAO PHARMA-B(02659): KJ101 received clinical trial approval for new indications.
SWIRE PROPERTIES (01972) released its annual performance with a net profit attributable to shareholders of HK$8.62 billion, representing a 27% year-on-year increase.
RECOMMEND
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026
